APOE4调节了DTI-ALPS指数与阿尔茨海默氏症病理之间的关联
Koung Mi Kang1,2, Chanrim Park3, Min Soo Byun4,5
1Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 29, 2025
概括
阿波利波蛋白E4 (APOE4) 基因变体加剧了ALPS指数测量的淋巴功能受损与大脑中β-粉样蛋白积累之间的联系. 这表明,APOE4载体的淋巴功能减弱,粉样β水平较高.
科学领域:
- 神经成像是一种神经成像.
- 神经退行发生神经退行.
- 遗传学 遗传学 是一个
背景情况:
- 淋巴功能障碍与阿尔茨海默氏病的发病有关.
- 阿波利波蛋白E4 (APOE4) 是阿尔茨海默病的主要遗传风险因素.
- 人类证据将APOE4,淋巴功能和粉样β (Aβ) 或沉积联系在一起是有限的.
研究的目的:
- 调查APOE4状态是否能缓和老年人淋巴功能障碍与Aβ或tau沉积之间的关系.
- 评估ALPS指数作为淋巴功能的非侵入性标记物的实用性及其与Aβ和tau的关联.
主要方法:
- 扩散张力成像 (DTI) 用于计算423名老年人的ALPS指数.
- 用[11C]匹兹堡化合物B (PiB) PET扫描测量了胺β (Aβ) 沉积量.
- 在132名参与者的子集中,使用[18F] AV-1451 PET扫描来评估陶沉积.
主要成果:
- 对于Aβ沉积,APOE4状态和ALPS指数之间的显著相互作用被发现.
- 较低的ALPS指数 (表明淋巴功能较差) 与较高的Aβ沉积有关,但仅在APOE4阳性个体中.
- 对于ALPS指数和沉积之间的关联,没有观察到APOE4的显著缓解.
结论:
- APOE4状态显著缓解了淋巴功能障碍和大脑Aβ负担之间的关联.
- ALPS指数可以作为一个有价值的非侵入性生物标志物来评估个体的Aβ沉积,特别是在APOE4.4的背景下.
- 这些发现突出了APOE4在加剧淋巴功能障碍对Aβ积累的有害影响中的作用.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806


